Tag: Herpes Zoster (Shingles)
ASA: Herpes Zoster Vaccine May Reduce Risk for Stroke
Risk significantly reduced for stroke events, acute ischemic strokes, hemorrhagic strokes in older adults
Adult Exposure to Chickenpox Cuts Shingles Risk
A modest but long-lasting protective effect was observed, but full protection not achieved
Two-Dose Course of Vaccine After HSCT Cuts Incidence of Zoster
Incidence of herpes zoster decreased during median 21-month follow-up after autologous HSCT
2003 to 2014 Saw Incidence of Herpes Zoster Drop in Children
Vaccinated children had 78 percent lower rate of HZ incidence than unvaccinated children
Herpes Zoster Ophthalmicus Cases Increased in 2004 to 2012
Highest rates of HZO seen in older adults, women, and in whites versus other racial groups
Recombinant Zoster Vaccine Cost-Effective in Simulation
Incremental cost-effectiveness ratio varied from $10,000 to $47,000 per QALY for RZV versus no vaccine
CDC Examines Safety of Recombinant Zoster Vaccine
Total of 4,381 reports of adverse events during first eight months of use; 3 percent were serious
Risk for Zoster Up Before Dx, During Tx of Hematologic Cancer
For solid organ cancers, the risk is greater among those receiving chemotherapy
Herpes Zoster Recombinant Vaccine Seems Most Effective
However, adjuvant recombinant subunit vaccine tied to more injection site adverse events
Robust Immune Responses for Herpes Zoster Subunit Vaccine
Humoral response seen for 97.8 percent of HZ/su vaccine recipients versus 2 percent of placebo
